Omalizumab: Anti-IgE Therapy in Severe Allergic Conditions

Background: The primary use of omalizumab (trade name Xolair) is for patients with severe, persistent and allergic asthma. Our aim was to evaluate the therapeutic efficacy of omalizumab as a treatment modality in patients with different allergic conditions. Methods: There were eleven patients, whom followed-up with omalizumab therapy in the Immunology - Allergy Clinic, were evaluated by the clinical findings of nasal polyposis, anaphylaxis history, drug allergy, latex allergy, food allergy, autoimmune urticaria, allergic rhino-conjunctivitis, atopic dermatitis, angioedema and venom allergy. Results: The patients, who had severe persistent asthma for periods ranging from 3 to 8 years, were enrolled in the study. Omalizumab was chosen as a potential new systemic therapy for the patients due to the clinical indication. Clinical symptoms of the all patients with severe persistent asthma were decreased. And in addition, asthma control test and pulmonary function tests were improved up. A severe anaphylactic reaction is prevented in a patient with 48 bee stings. Conclusion: This clinical follow-up of omalizumab treated patients with severe persistent asthma and many different allergic conditions, suggests omalizumab is an effective therapy for asthma and different allergic conditions.

[1]  A. Kargi,et al.  Systemic levels of ceruloplasmin oxidase activity in allergic asthma and allergic rhinitis , 2012, Immunopharmacology and immunotoxicology.

[2]  A. Yalcin,et al.  The relation of sTRAIL levels and quality of life in severe persistent allergic asthma patients using omalizumab. , 2012, Medical science monitor : international medical journal of experimental and clinical research.

[3]  A. Kargi,et al.  Serum-soluble TRAIL levels in patients with severe persistent allergic asthma: Its relation to omalizumab treatment , 2012, Medical science monitor : international medical journal of experimental and clinical research.

[4]  A. Kargi,et al.  278 Total Antioxidant Capacity, Hydrogen Peroxide, Malondialdehyde and Total Nitric Oxide Concentrations in Patients With Severe Persistent Allergic Asthma: Its Relation to Omalizumab Treatment , 2012, Clinical laboratory.

[5]  M. Bilò.  Anaphylaxis caused by Hymenoptera stings: from epidemiology to treatment , 2011, Allergy.

[6]  C. Filis,et al.  Omalizumab monotherapy for bee sting and unprovoked "anaphylaxis" in a patient with systemic mastocytosis and undetectable specific IgE. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[7]  K. Bergmann,et al.  Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co‐morbid seasonal allergic asthma , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[8]  R. Zeldin,et al.  Treatment of chronic autoimmune urticaria with omalizumab. , 2008, The Journal of allergy and clinical immunology.

[9]  B. Przybilla,et al.  [Venom immunotherapy. Side effects and efficacy of treatment]. , 2008, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[10]  S. Schwartz,et al.  Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab. , 2007, The Journal of allergy and clinical immunology.

[11]  S. Spector,et al.  Effect of omalizumab on patients with chronic urticaria. , 2007, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[12]  M. Chehade.  IgE and non-IgE-mediated food allergy: treatment in 2007 , 2007, Current opinion in allergy and clinical immunology.

[13]  H. Fox,et al.  Improvement in quality of life with omalizumab in patients with severe allergic asthma , 2006, Current medical research and opinion.

[14]  F. Bonifazi,et al.  Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice , 2005, Allergy.

[15]  J. Bousquet,et al.  The effect of treatment with omalizumab, an anti‐IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma , 2005, Allergy.

[16]  S. Spector,et al.  Stinging insect hypersensitivity: a practice parameter update 2011. , 2004, The Journal of allergy and clinical immunology.

[17]  E. Chilvers,et al.  Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate‐to‐severe) allergic asthma , 2004, Allergy.

[18]  J. Bousquet,et al.  Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthma , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[19]  O. Noga,et al.  Omalizumab inhibits allergen challenge-induced nasal response , 2004, European Respiratory Journal.

[20]  V. Le Gros,et al.  Effect of omalizumab in health care workers with occupational latex allergy. , 2004, The Journal of allergy and clinical immunology.

[21]  T. Casale,et al.  Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[22]  T. Casale,et al.  Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. , 2001, JAMA.

[23]  H. Mosbech,et al.  Side‐effects of insect venom immunotherapy:results from an EAACI multicenter study , 2000, Allergy.

[24]  T. Haahtela,et al.  Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. , 2000, The Journal of allergy and clinical immunology.

[25]  P. Shekelle,et al.  Clinical guidelines: developing guidelines. , 1999, BMJ.

[26]  U. Müller,et al.  Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. , 1998, The Journal of allergy and clinical immunology.

[27]  D. Golden,et al.  Discontinuing venom immunotherapy: outcome after five years. , 1996, The Journal of allergy and clinical immunology.

[28]  J. Bousquet,et al.  Emergency treatment of allergic reactions to Hymenoptera stings , 1991, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[29]  J. Bousquet,et al.  Immunotherapy with Hymenoptera venoms , 1987, Allergy.

[30]  A. Akman,et al.  Jessner lymphocytic infiltrate as a side effect of bee venom immunotherapy. , 2012, Journal of investigational allergology & clinical immunology.

[31]  E. Terzioğlu,et al.  Occupational disease of healthcare workers: latex allergy. , 2011 .

[32]  R. Katz,et al.  Effects of omalizumab in patients with food allergy. , 2010, Allergy and asthma proceedings.

[33]  P. Demoly,et al.  Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. , 2009, Journal of investigational allergology & clinical immunology.